文献速递临床试验与 GCP基础与转化研究

食管切除术对比根治性放化疗治疗内镜黏膜下剥离术后cN0-pT1b食管鳞癌:多中心随机对照试验方案(Ad-ESD试验)

Esophagectomy versus definitive chemoradiotherapy for patients with clinical stage N0 and pathological stage T1b esophageal squamous cell carcinoma after endoscopic submucosal dissection: study protocol for a multicenter randomized controlled trial (Ad-ESD Trial).
PubMed 文献 · Trials · 2020-07-01

这是首个比较两种治疗方案的III期RCT,旨在为这类患者的初级挽救治疗提供高质量证据。

要点

  • ESD后pT1b cN0食管鳞癌患者随机接受食管切除术或dCRT。
  • 主要终点为5年总生存期,随访60个月。
  • 次要终点包括生活质量、不良事件、3年总生存率和无复发生存率。

核心结论

  • 该试验旨在明确dCRT是否较食管切除术为ESD后cN0-pT1b ESCC患者带来更多获益。

关键数值与推荐

  • 临床淋巴结状态通过计算机断层扫描(CT)和正电子发射断层扫描-计算机断层扫描(PET-CT)等影像学检查评估。
  • 病理肿瘤状态在内镜黏膜下剥离术(ESD)后诊断。
  • 主要终点为5年总生存期;次要终点包括生活质量、相关不良事件、3年总生存率和无复发生存率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Esophagectomy is still advised as an additional treatment for pathological T1b (pT1b) esophageal squamous cell carcinoma (ESCC) following attempted endoscopic resection (ER). ER followed with definitive chemoradiotherapy (dCRT) has shown increased quality of life as well as comparable oncological outcomes to esophagectomy. However, there is no well-designed phase III trial to compare the two treatments for patients with pT1b ESCC. METHODS: One hundred seventy-six patients with clinical stage N0 (cN0) and pT1b ESCC will be recruited at three centers and randomly assigned to the esophagectomy group or the dCRT group. The clinical lymph node status will be measured by image examination, including computer tomography and positron emission tomography-computed tomography. The pathological tumor status will be diagnosed after endoscopic submucosal dissection (ESD). All patients will be followed up for 60 months after randomization. The primary endpoint is 5-year overall survival. The secondary endpoints are quality of life, related adverse events, 3-year overall survival, and relapse-free survival rates. DISCUSSION: To the best of our knowledge, this is the first phase III randomized controlled trial to compare esophagectomy and dCRT for patients with cN0-pT1b ESCC after ESD. Based on the results of this study, we will show whether dCRT will benefit patients more than esophagectomy, which will contribute more high-quality evidence to the primary salvage treatment for these patients. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04135664 . Registered on Aug. 10, 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Yang Y, Su Y, Zhang X, et al. Esophagectomy versus definitive chemoradiotherapy for patients with clinical stage N0 and pathological stage T1b esophageal squamous cell carcinoma after endoscopic submucosal dissection: study protocol for a multicenter randomized controlled trial (Ad-ESD Trial). Trials. 2020. PMID: 32611448. doi:10.1186/s13063-020-04461-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。